The CXC Chemokines IP-10 and Mig Are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor[1]

Charles S. Tannenbaum,[2]* Raymond Tubbs,*† David Armstrong,* James H. Finke,* Ronald M. Bukowski,*† and Thomas A. Hamilton*

The role of the non-ELR-containing CXC chemokines IP-10 and Mig in antitumor activity induced by systemic treatment with IL-12 was examined in mice bearing the murine renal adenocarcinoma RENCA. IL-12 treatment produces a potent antitumor effect that is associated with tumor infiltration by CD8⁺ T lymphocytes. The regression of tumor is associated with the elevated expression of the IFN-γ-inducible chemokines IP-10 and Mig within the tumor tissue. IP-10 and Mig have been shown to function as chemoattractants for activated T lymphocytes. In animals treated with rabbit polyclonal Abs specific for IP-10 and for Mig, the IL-12-induced regression of RENCA tumors was partially abrogated. This effect was associated with a dramatic inhibition of T cell infiltration. Thus, it appears that IL-12-dependent, T cell-mediated antitumor activity requires the intermediate expression of IP-10 and Mig to recruit antitumor effector T cells to the tumor site. *The Journal of Immunology,* 1998, 161: 927–932.

Many cytokines, either administered systemically or expressed as transgenes by tumors, have been shown to promote significant antitumor activity in rodents (1–6). IL-12 is one of the most effective cytokines in such settings and results in high frequency cure of established, poorly immunogenic tumors (6–12). The mechanisms by which IL-12 induces antitumor function are believed to include the promotion of potent antitumor immunity in which T cells of the Th1 phenotype predominate (13–17). IL-12-mediated antitumor activity is dependent upon the presence of both CD4⁺ and CD8⁺ T lymphocytes and upon the production of IFN-γ (7, 10, 11). A recent report from this laboratory demonstrated that the antitumor response stimulated by IL-12 correlated strongly with the production of the IFN-γ-inducible chemokine IP-10 by cells within the tumor bed (6). IP-10 is a member of the CXC family of chemokines but is missing the ELR amino acid sequence motif that has been linked with neutrophil chemotaxis. The absence of this function reflects the inability of non-ELR CXC chemokines to bind with the IL-8R (CXCR1[3] and CXCR2) (18–20). Recently, a receptor exhibiting specificity for IP-10 and a related, non-ELR CXC chemokine termed Mig (21, 22) has been identified (CXCR3) whose expression is restricted to activated T cells (23). This finding suggested the hypothesis that IL-12 induces expression of IP-10 and Mig chemokines secondary to the production of IFN-γ and thereby stimulates enhanced recruitment of effector immune cells to the tumor site.

The goal of the present study was to test this hypothesis by examining the antitumor activity of IL-12 in animals given Abs to block the function of IP-10 and Mig. In BALB/c mice bearing established RENCA tumors, IL-12 treatment produces effective tumor regression (6, 7). Treatment with a mixture of rabbit polyclonal Abs that recognize IP-10 and Mig produced a significant abrogation of the IL-12-mediated antitumor function that was associated with a marked reduction in the infiltration of the tumor tissue with perforin-expressing CD8⁺ T cells.

Materials and Methods

Reagents

Dulbecco's PBS was purchased from Mediatech (Washington DC). Agarose, SDS, guanidine isothiocyanate, cesium chloride, and phenol were purchased from Life Technologies (Gaithersburg, MD). Boehringer Mannheim (Indianapolis, IN) was the source of restriction endonucleases, proteinase K, nick translation kits, random primer kits, reverse transcriptase, RNase inhibitor, and Taq polymerase. [32P]dCTP was purchased from Du-Pont-New England Nuclear Research Products (Boston, MA). Reagents for SDS-PAGE and protein determination were obtained from Bio-Rad Laboratories (Richmond, CA). Recombinant murine IL-12 was provided by both Genetics Institute (Boston, MA) and Dr. Michael Brunda (Hoffmann-La Roche, Nutley, NJ). Vector Laboratories (Burlingame, CA) was the source of biotinylated goat anti-rat IgG. Peroxidase-labeled streptavidin, biotinylated anti-rat IgG, and chromogenic substrate for immunohistology were purchased from Ventana Medical Systems (Tuscon, AZ). Rat mAbs against mouse CD4 and CD8 were purchased from Becton Dickinson (Mountain View, CA), and a mAb against mouse CD31 was provided by Dr. Alberto Mantovani (Mario Negri Institute, Milan, Italy).

Animals

Male BALB/c mice, 6 to 8 wk old, were purchased from the National Institutes of Health (Bethesda, MD) and housed in a specific pathogen-free animal facility. Animals were maintained in microisolator cages with autoclaved food and bedding to minimize exposure to viral and microbial pathogens (24).

Tumors

RENCA is a spontaneously arising murine renal cell carcinoma and was isolated and maintained as described previously (25). Routinely, 4 × 10⁵ tumor cells in 0.1 ml of PBS were inoculated s.c. Fourteen days following tumor inoculation, animals received 0.5 μg of recombinant murine IL-12 i.p. daily for the duration of the experiment, while control animals received vehicle alone. Tumor volumes were measured daily with a micrometer in two dimensions, and tumor size was estimated according to the formula: (smallest diameter)² × (longest diameter). Tumor growth under different treatment conditions was statistically analyzed using the Wilcoxon rank sum test. The p values obtained represent the two-sided value.

Preparation of Abs

Rabbit polyclonal Abs to Mig and IP-10 were produced by Biosynthesis (Lewisville, TX) using synthetic peptides selected from the IP-10 and Mig protein sequences (CIHIDDGPVRMRAIGK and CISTSRGTIHYKSLK DLKQFAPS, respectively) coupled to carrier protein KLH.

Western blot analysis

RENCA cells in 100-mm diameter petri dishes were cultured in serum- and protein-free hybridoma medium (Sigma, St. Louis, MO) with or without stimulation by IFN-γ for 24 h. Supernatant medium was dialyzed overnight against 25 mM NaPO4, pH 7.4, and then mixed with a 40-μl (bed volume) aliquot of heparin-Sepharose beads for 16 h at room temperature. The beads were washed in buffer and then boiled in the presence of 2% SDS sample buffer (26), and the eluted samples were separated by SDS-PAGE (15%). Proteins were then transferred to Nitrobind transfer membranes (Micron Separations, Westborough, MA) using a semidry transfer cell (Bio-Rad) for 45 min at 450 mA constant current in transfer buffer (48 mM Tris, 39 mM glycine, and 20% methanol, pH 9.2). Blots were blocked with 5% nonfat milk in TBST (0.15 M NaCl, 0.1% Tween-20, and 50 mM Tris, pH 7.4) at 20°C for 2 h, then incubated overnight with rabbit polyclonal Abs against IP-10 or Mig in 5% nonfat milk TBST solution (in some reactions, peptide against which the Ab was initially raised was included as a competitor at 1 μg/ml). After washing three times in TBST, filters were incubated at room temperature for 1 h with goat anti-rabbit IgG conjugated to horseradish peroxidase and then washed again as described above. Ab binding was detected using the ECL kit from Amersham (Arlington Heights, IL).

Immunohistologic analysis

Immunohistology was performed as previously described (6, 25, 27). Tissues were snap-frozen in isopentane precooled in liquid nitrogen until sectioned. Frozen tissue sections (6 μm) were prepared, air-dried, fixed in cold reagent grade acetone for 10 min, and air dried. Rat mAbs against mouse CD8 or CD31 were applied at concentrations optimally titrated against mouse thymus or mouse lung, respectively, and linked to streptavidin-peroxidase by biotinylated rabbit anti-rat IgG using the Ventana 320 automated immunostainer (Ventana, Tuscon, AZ). The chromogenic substrate aminocarbazole/H$_2$O$_2$ followed by hematoxylin counterstaining was used to visualize positive reactivity. To quantify T cell infiltration into tumor tissues, the number of cells showing anti-CD8 reactivity in a series of high power fields was counted in several tumors from each experiment. Because the tumor tissue exhibited variable degrees of necrosis and variable distribution of T cell infiltrates, only fields of nonnecrotic tumor containing the highest T cell numbers for each experimental condition were included in the analysis.

Plasmids

Plasmids with inserts encoding murine IP-10 and perforin were previously described (6). A DNA fragment encoding a portion of the murine Mig mRNA sequence was obtained by RT-PCR using primers flanking the coding region and RNA derived from IFN-γ-stimulated mouse peritoneal macrophages. The PCR product was cloned into the plasmid pGEM 4Z. The methods for plasmid DNA preparation were previously described (6).

Analysis of mRNA expression in tumor tissue

Total cellular RNA was extracted from 0.3 to 0.5 g of whole tumor tissue by homogenization with a Polytron sonicator/homogenizer (Brinkmann Instruments, Westbury, NY) for 1 min in guanidine isothionate followed by ultracentrifugation through cesium chloride according to previously described methods (28, 29). Northern hybridization analysis was conducted as described previously (30, 31). Equal amounts of RNA (20 μg) were denatured, separated by electrophoresis in an agarose-formaldehyde gel, and blotted by capillary transfer onto nylon membranes. The blots were prehybridized 6 to 18 h at 42°C in 50% formamide, 1% SDS, 5× SSC, 1× Denhardt's solution (0.02% Ficoll, 0.02% BSA, and 0.02% polyvinylpyrrolidine). 0.25 mg/ml denatured salmon sperm DNA, and 50 mM sodium phosphate buffer, pH 6.5. Hybridization was conducted at 42°C for 12 to 18 h with 10^7 cpm of denatured probe. The filters were washed twice for 15 min each time at 55°C in 0.1% SDS-0.5× SSC. The blots were then exposed using XAR-5 x-ray film (Eastman Kodak, Rochester, NY) with DuPont (Wilmington, DE) Cronex Lightening Plus intensifying screens at −70°C. Expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as an internal control and was applied in all experiments.

Semiquantitative RT-PCR analysis of perforin mRNA was conducted as reported previously (6, 25, 32). One microgram of total RNA was amplified


FIGURE 1. Expression of IP-10 and Mig mRNA in tumor tissue from untreated and IL-12-treated mice. BALB/c mice were inoculated with 4 × 10^5 RENCA cells s.c. Groups of six animals were not treated or were treated i.p. with IL-12 (0.5 μg/mouse/day) beginning on day 14 for 10 days before harvest of tumor tissue and preparation of total RNA. Twenty micrograms of RNA from each animal was subjected to Northern hybridization analysis as described in Materials and Methods, using radiolabeled cDNAs corresponding to the indicated mRNAs. Similar results were obtained in three separate experiments.

using an oligo(dT) antisense primer and AMV reverse transcriptase at 42°C for 1 h. The RT reaction products were used undiluted or at a 1/10 dilution for PCR amplification using 20 mM sense and antisense primers (see below) and Taq polymerase. PCR reactions were conducted in a Perkin-Elmer/Cetus DNA Thermal Cycler for 15 cycles (denaturation, 1 min, 94°C; annealing, 1 min, 60°C; amplification, 2 min, 72°C). The primer sequences used were as follows: perforin antisense primer, GGTGGAGT GGAGGTTTTTGTACC; and perforin sense primer, CAGAATGCAAG CAGAAGCACAAG (perforin product size, 486 bp). These primers were chosen from separate exons to ensure that products derived from mRNA and contaminating genomic DNA could be distinguished. The PCR products were separated by agarose gel electrophoresis and visualized by Southern hybridization analysis using radiolabeled cDNA encoding a portion of the perforin gene sequence.

Results

BALB/c mice were injected s.c with 4 × 10^5 RENCA tumor cells, and IL-12 treatment (0.5 μg/day i.p.) was initiated on day 14. Tumors in animals receiving saline vehicle grew progressively, while tumors in IL-12-treated animals regressed following a modest delay, confirming previous work (6). To examine the expression of chemokines at the tumor site, total RNA was prepared from tumor tissue isolated from control or IL-12-treated animals and analyzed for the expression of the IFN-γ-inducible chemokine mRNAs by Northern hybridization (Fig. 1). IP-10 and Mig mRNA were readily detected in tumor tissue from IL-12-treated animals, but not in tumors from untreated animals.

To determine the functional importance of chemokine expression in the IL-12-mediated antitumor activity, Abs against mouse IP-10 and Mig were raised in rabbits as described in Materials and Methods. The Abs were characterized by examining reactivity in Western blots with proteins secreted by cultured RENCA cells stimulated with IFN-γ (Fig. 2). While Ab to IP-10 reacts with a single band of approximately 8 kDa present only in the medium from IFN-γ-stimulated cells, the Ab to Mig showed specific recognition of three IFN-γ-inducible peptide species of approximately 14, 10, and 8 kDa. Specificity was further demonstrated by competition with peptides used as immunogens (Fig. 2). The heterogeneity evident in the Mig protein may derive from post-translational modification and/or from degradation following secretion.

These Abs were subsequently employed to assess the roles of IP-10 and Mig in IL-12-mediated regression of RENCA tumors. BALB/c mice bearing 14-day-old RENCA tumors were treated with IL-12 (0.5 μg/animal/day) for 15 days with or without control

FIGURE 2. Analysis of IP-10 and Mig protein expression in RENCA cells in culture. Confluent cultures of RENCA cells in 100-mm petri dishes were not treated or were treated with 100 U/ml of murine IFN-γ for 18 h in serum- and protein-free culture medium. Supernatant medium from each sample was dialyzed, adsorbed to heparin-Sepharose beads, eluted, and separated by 15% SDS-PAGE. Proteins were transferred to nitrocellulose filters and analyzed separately for reactivity with Abs against IP-10 or Mig in presence or the absence of specific peptide immunogen (1 μg/ml) as indicated. Similar results were obtained in two separate experiments.

or anti-chemokine Ig. Animals in groups of 12 received 1 mg of nonimmune Ig or anti-Mig and/or anti-IP-10 Ig i.p. 1 day before the initiation of IL-12 treatment and at 3-day intervals (0.5 mg each) through the completion of the experiment. Tumors grew progressively in otherwise untreated mice and in mice that were given nonimmune rabbit Ig, while growth of tumors in animals treated with IL-12 was inhibited (Fig. 3). In two separate experiments, the combination of anti-IP-10 and anti-Mig significantly reduced the IL-12-mediated inhibition of tumor growth ($p \le 0.005$ for the group treated with IL-12 and nonimmune Ig vs that treated with IL-12 and anti-IP-10 and anti-Mig Ig). Indeed, by day 15 of treat-

ment, tumors from animals receiving both anti-chemokine Abs were approximately fivefold larger than tumors from animals treated with IL-12 alone or with nonimmune Ig. While treatments with anti-IP-10 alone had no detectable effect on IL-12-driven antitumor function, use of Ab to Mig alone produced a small reduction of the response to IL-12, which was not statistically significant. These results indicate that Mig and IP-10 may be necessary for IL-12-mediated anti-tumor activity.

It has recently been shown that Mig and IP-10 mediate chemotaxis of activated T cells via interaction with the CXCR3 receptor (22, 23, 33). Furthermore, the antitumor activity of IL-12 is heavily dependent on T cells (7, 10). To determine whether the observed inhibition of IL-12-mediated antitumor activity by Abs against Mig and IP-10 might result from abrogation of T cell recruitment into the tumor bed, tumor tissue from animals treated with IL-12 along with control or anti-chemokine Abs was analyzed for T cell infiltration by immunohistology. Tumors prepared from IL-12-treated animals were heavily infiltrated with CD8⁺ T cells, confirming previous findings (6) (Fig. 4A). Tumor tissue from animals receiving Abs to both IP-10 and Mig throughout the course of IL-12 treatment exhibited a dramatic reduction in CD8⁺ T cell infiltration (this effect was observed in all four RENCA tumors examined and in two separate experiments). Quantification of CD8⁺ T cell infiltration was conducted by comparing numbers of T cells in sections of tumors from different treatment conditions (Fig. 4B). In each treatment group regions of the tumor that contained the highest level of T cell infiltration were identified, and the CD8⁺ T cells were enumerated in a series of high power fields. Regions of the tumor that exhibited necrosis were excluded. This analysis confirms the reduction in T cell numbers within tumors from mice receiving IL-12 plus anti-IP-10 and anti-Mig compared with those in animals receiving IL-12 alone or in the presence of nonspecific Ab. Furthermore, an intermediate reduction in T cell infiltration was observed in animals receiving IL-12 and only anti-Mig Ab. The number of CD4⁺ T cells infiltrating the tumors in IL-12-treated animals was also reduced in animals receiving the anti-chemokine Ig (data not shown).

Previous studies from this laboratory demonstrated that perforin mRNA was strongly expressed in regressing RENCA tumors from mice treated with IL-12 (6). Perforin is a product of cytotoxic T cells and NK cells and may contribute to the antitumor activity of IL-12 (34–37). Portions of the RENCA tumors from the experiments shown in Figure 4 were used to prepare total RNA for semiquantitative analysis of perforin mRNA levels using RT-PCR. The results obtained provide further confirmation of the histologic data

FIGURE 3. Abs to IP-10 and Mig inhibit IL-12-mediated antitumor activity. BALB/c mice were inoculated with 4 × 10⁵ RENCA cells s.c. On day 14, groups of 12 animals were treated with IL-12 alone or with control or anti-chemokine Abs as indicated. IL-12 (0.5 μg/animal/day) was administered daily, and Abs were given 1 day before IL-12 and at 3-day intervals thereafter. Tumor size was measured as described in *Materials and Methods* daily through 15 days of treatment. Results are presented as the mean ± SEM. Similar results were obtained in two separate experiments.

A

FIGURE 4. Abs to IP-10 and Mig block CD8⁺ T cell infiltration in IL-12-treated RENCA tumors. *A*, RENCA tumors were obtained from animals treated, or not, with IL-12 in the presence or the absence of either control or anti-IP-10 and anti-Mig Abs and were processed for immunohistology to detect the presence of CD8⁺ T cells as described in *Materials and Methods*. *B*, High power fields from each histologic section were analyzed for T cell infiltration as described in *Materials and Methods*. Results are presented as the mean ± SEM. Similar results were obtained in two separate experiments.

B

(Fig. 5). Tumors from IL-12-treated mice had high levels of perforin mRNA compared with untreated tumors, in which perforin mRNA was not detectable. Tumor tissue from animals treated with IL-12 and nonimmune rabbit Ig also expressed high levels of perforin mRNA, while tumor from animals treated with IL-12 and anti-Mig/anti-IP-10 had significantly reduced perforin expression. In this experiment, the reduction in perforin mRNA from animals receiving Ab to Mig alone is also evident.

Both IP-10 and Mig have been shown to inhibit angiogenesis in vivo and in vitro (38–41). Furthermore, IL-12 has been reported to exhibit antiangiogenic activity, and this has been attributed to IL-12-dependent expression of IP-10 (42, 43). To test the possibility that our Abs were inhibiting IL-12-mediated antitumor function by blocking the inhibition of angiogenesis, we assessed the relative intratumoral density of endothelial cells based upon immunoreactivity with a mAb against CD31, a marker highly specific for vas-

cular endothelium. The density of CD31-positive cells present in the tumor was not different between experimental groups (data not shown). Tumors from IL-12-treated mice exhibited significant necrosis, and examination of endothelial cell density was restricted to nonnecrotic areas of the tumor; the distribution and density of CD31 staining were, however, equivalent in all fields examined regardless of treatment condition. Because tumor tissue was rapidly destroyed in T cell-dependent fashion following the initiation of IL-12 treatment, this result may not reflect the angiostatic potential of IL-12 or IP-10 and Mig.

Discussion

The goal of the present study was to test the importance of the chemokines IP-10 and Mig in IL-12-mediated regression of RENCA tumor growth. Although IL-12 was originally identified

FIGURE 5. Abs to IP-10 and Mig reduce perforin mRNA levels in IL-12-treated RENCA tumors. Tumors were obtained from animals treated with IL-12 with or without control or anti-chemokine Abs as indicated and were used to prepare total RNA. RNA samples from individual tumors was used for semiquantitative RT-PCR detection of perforin mRNA as described in *Materials and Methods*. PCR products were separated on agarose gels, blotted onto nylon membrane, and hybridized with a radiolabeled cDNA corresponding to perforin mRNA. Similar results were obtained in two separate experiments.

as a stimulus of NK cells, it has since has been characterized as an important cytokine in many physiologic and pathophysiologic settings (8, 14, 44–46). IL-12-stimulated antitumor function is dependent upon the induction of IFN-γ and the presence of both CD4$^+$ and CD8$^+$ T cells (7, 9, 10). The observation that IL-12 treatment induces high levels of IFN-γ in tumor-bearing nude mice without marked antitumor effects indicates that IFN-γ is necessary, but not sufficient, for IL-12-mediated antitumor function (7, 9, 10). We hypothesize that the remarkable antitumor efficacy of IL-12 derives from its ability both to enhance the T cell-mediated immune response to the tumor and to promote the infiltration of the tumor by activated effector T cells. Our results indicate that this latter objective is achieved via the IFN-γ-mediated production of the non-ELR-containing CXC chemokines, IP-10 and Mig, and is supported by the following observations. 1) Rabbit Abs to IP-10 and Mig, when provided in combination, reduce the antitumor activity of IL-12 against established RENCA tumors growing s.c. 2) The anti-chemokine Ab treatment results in a marked reduction in the infiltration of tumors by CD4$^+$ and CD8$^+$ T cells and reduced expression of mRNA encoding the cytotoxic T cell effector molecule perforin. 3) There was no detectable change in the tissue density of endothelial cells within tumors receiving any of the experimental treatments.

While the effect of Ab treatment on antitumor function is not complete, the results clearly indicate that both chemokine gene products are functionally important components of the IL-12 antitumor mechanism. Since both Mig and IP-10 bind CXCR3 and mediate T cell chemotaxis (23), it is not surprising that both Abs should be required to achieve neutralization of IL-12-mediated T cell infiltration and tumor growth inhibition. Although statistically significant effects were only observed when Abs to both Mig and IP-10 were administered, anti-Mig Ab alone appeared to produce a reduction in the action of IL-12 in several animals. In this regard Mig has also been shown to exhibit higher potency than IP-10 in T cell chemotaxis (22, 23).

The results presented here suggest that the effect of anti-chemokine Abs on IL-12-driven tumor regression is a direct consequence of their ability to block chemokine-mediated recruitment of activated T cells to the site. Such a scenario is consistent with an early report showing that IP-10 expression by tumor cells could promote a strong T cell-dependent antitumor effect (47). Both IP-10 and Mig have been shown to exhibit other nonchemotaxis-related activities that may be relevant to the antitumor effects of IL-12. Specifically, both chemokines have been reported to exhibit potent antiangiogenic activity in vitro and in vivo (38–41). Interestingly, CXC chemokines that possess an ELR amino acid motif immediately preceding the CXC motif have been demonstrated to be angiogenic agents, while those that do not have the ELR sequence are angiogenesis inhibitors (41). Indeed, the balance of

expression of ELR$^+$ and ELR$^-$ CXC chemokines within a tumor has been proposed as an important determinant of progressive tumor growth and metastasis (41, 48). This hypothesis is supported by the finding that IP-10 expression by human lung tumors in SCID mice is associated with reduced tumor growth potential, while neutralization of IP-10 enhances growth (49). In our studies the density of endothelial cells within tumor tissue did not change in the presence of IL-12 treatment (and was not influenced by Abs to IP-10 or Mig). This result should not, however, be interpreted to mean that IL-12 did not produce an angiostatic effect in RENCA tumors. Because RENCA tumors are rapidly destroyed in immunocompetent mice treated with IL-12, the angiogenesis inhibitory action of IL-12 may be masked by its potent effect on the development of antitumor T cells. Thus, these experiments do not allow a direct determination of the antiangiogenic activity of IP-10 and Mig. In addition to effects on neovascularization, both IP-10 and Mig have also been reported to cause focal tumor necrosis when injected intratumorally or when expressed by tumor cells (50, 51). As discussed above with regard to angiogenesis inhibition, we cannot determine whether IP-10 and/or Mig are responsible for enhanced tumor necrosis because of the dominant role of T cell activity in this model.

There have been numerous reports attesting to the ability of CC and CXC chemokines to promote antitumor activity when expressed as transgenes by experimental tumors (39, 52–58). While there are examples where chemokine expression alone appears to be sufficient to promote an efficacious antitumor response, chemokines may function best in cooperation with other cytokine agents. For example, tumor cells transduced to express lymphotactin, a chemokine with specificity for T cells, grew normally when injected alone, but were destroyed rapidly in mice cotreated with IL-2 (59). The results of the present study support the concept of cooperativity between chemokines and other cytokines in antitumor strategies. IL-12 is able to promote chemokine expression through the enhanced expression of IFN-γ; this may not be sufficient, however, and IL-12 also promotes expansion and activation of tumor-specific T lymphocytes. The IFN-γ-induced chemokines may cooperate by recruiting such cells to the tumor site. One consequence of increased T cell infiltration would be additional IFN-γ production and further enhancement of chemokine synthesis. It is also likely that the nonchemotactic functions of Mig and IP-10, such as inhibition of angiogenesis, can act cooperatively with the chemotactic functions to promote more efficacious antitumor function.

References

1. Sayers, T. J., T. A. Wiltrout, K. McCormick, C. Husted, and R. H. Wiltrout. 1990. Antitumor effects of α-interferon and γ-interferon on a murine renal cancer (Renca) in vitro and in vivo. *Cancer Res. 50:5414.*
2. Brunda, M. J., and R. B. Wright. 1986. Differential antiproliferative effects of combinations of recombinant interferons α and γ on two murine tumor cell lines. *Int. J. Cancer 37:287.*

3. Brunda, M. J., V. Sulich, and D. Bellatoni. 1987. The anti-tumor effect of re-
combinant interferon α or γ is influenced by tumor location. *Int. J. Cancer 40:
807.*

4. Mule, J. J., J. C. Yang, R. Lafreniere, S. Shu, and S. A. Rosenberg. 1987. Iden-
tification of cellular mechanisms operational in vivo during the regression of
established pulmonary metastases by systemic administration of high-dose re-
combinant interleukin-2. *J. Immunol. 139:285.*

5. Kedar, E. and E. Klein. 1992. Cancer immunotherapy: are the results discourag-
ing? Can they be improved? *Adv. Cancer Res. 59:245.*

6. Tannenbaum, C. S., N. Wicker, D. Armstrong, R. Tubbs, J. Finke,
R. M. Bukowski, and T. A. Hamilton. 1996. Cytokine and chemokine expression
in tumors of mice receiving systemic therapy with IL-12. *J. Immunol. 156:693.*

7. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard,
M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic
activity of interleukin 12 against murine tumors. *J. Exp. Med. 178:1223.*

8. Brunda, M. J. 1994. Interleukin-12. *J. Leukocyte Biol. 55:280.*

9. Brunda, M. J., and M. K. Gately. 1994. Antitumor activity of interleukin-12. *Clin.
Immunol. Immunopathol. 71:253.*

10. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik,
M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and
M. T. Lotze. 1994. Recombinant interleukin-12 (IL-12) administration induces tumor
regression in association with interferon-γ production. *J. Immunol. 153:1697.*

11. Brunda, M. J., L. Luistro, J. A. Hendrzak, M. Fountoulakis, G. Garotta, and
M. K. Gately. 1995. Role of interferon-γ in mediating the antitumor efficacy of
interleukin-12. *J. Immunother. 17:71.*

12. Brunda, M. J., L. Luistro, L. Rumennik, R. B. Wright, M. Dvorozniak,
A. Aglione, J. M. Wigginton, R. H. Wiltrout, J. A. Hendrzak, and A. V. Palleroni.
1996. Antitumor activity of interleukin 12 in preclinical models. *Cancer Che-
mother. Pharmacol. 38(Suppl.):S16.*

13. Trinchieri, G. 1993. Interleukin-12 and its role in the generation of Th1 cells.
Immunol. Today 14:335.

14. Trinchieri, G., and P. Scott. 1994. The role of interleukin 12 in the immune
response, disease and therapy. *Immunol. Today 15:460.*

15. Manetti, R., P. Parronchi, M. G. Giudizi, M.-P. Piccinni, E. Maggi, G. Trinchieri,
and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12
[IL-12]) induces T helper type 1 (Th1)-specific immune response and inhibits the
development of IL-4-producing Th cells. *J. Exp. Med. 177:1199.*

16. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, F. Loudon,
F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification
of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biolog-
ical effects on human lymphocytes. *J. Exp. Med. 170:827.*

17. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immuno-
regulatory functions that bridge innate resistance and antigen-specific adaptive
immunity. *Annu. Rev. Immunol. 13:251.*

18. Clark-Lewis, I., B. Dewald, M. Loetscher, B. Moser, and M. Baggiolini. 1994.
Structural requirements for interleukin-8 function identified by design of analogs
and CXC chemokine hybrids. *J. Biol. Chem. 269:16075.*

19. Baggiolini, M., P. Loetscher, and B. Moser. 1995. Interleukin-8 and the chemo-
kine family. *Int. J. Immunopharmacol. 17:103.*

20. Clark-Lewis, I., K.-S. Kim, K. Rajarathnam, J.-H. Gong, B. Dewald, B. Moser,
M. Baggiolini, and B. D. Sykes. 1995. Structure-activity relationships of chemo-
kines. *J. Leukocyte Biol. 57:703.*

21. Farber, J. M. 1990. A macrophage mRNA selectively induced by gamma-inter-
feron encodes a member of the platelet factor 4 family of cytokines. *Proc. Natl.
Acad. Sci. USA 87:5238.*

22. Liao, F., R. L. Rabin, J. R. Yannelli, L. G. Koniaris, P. Vanguri, and J. M. Farber.
1995. Human Mig chemokine: biochemical and functional characterization.
J. Exp. Med. 182:1301.

23. Loetscher, M., B. Gerber, P. Loetscher, S. A. Jones, L. Piali, I. Clark-Lewis,
M. Baggiolini, and B. Moser. 1996. Chemokine receptor specific for IP10 and Mig:
structure, function and expression in activated T lymphocytes. *J. Exp. Med. 184:963.*

24. Meltzer, M. S. 1976. Tumoricidal response in vitro of peritoneal macrophages
from conventionally housed and germ-free nude mice. *Cell. Immunol. 22:176.*

25. Sonouchi, K., T. A. Hamilton, C. S. Tannenbaum, R. R. Tubbs, R. Bukowski, and
J. H. Finke. 1994. Chemokine gene expression in the murine renal cell carcinoma,
RENCA, following treatment in vivo with interferon-α and interleukin-2.
Am. J. Pathol. 4:747.

26. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. *Nature 227:680.*

27. Sheibani, K., and R. R. Tubbs. 1984. Enzyme immunohistochemistry: technical
aspects. *Semin. Diag. Pathol. 1:235.*

28. Chirgwin, J. M., R. J. Pryzbyla, R. J. MacDonald, and W. J. Rutter. 1979. Iso-
lation of biologically active RNA from sources enriched in ribonuclease. *Bio-
chemistry 18:5295.*

29. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular Cloning: A Lab-
oratory Manual.* Cold Spring Harbor Laboratory, Cold Spring Harbor.

30. Hamilton, T. A., N. Bredon, Y. Ohmori, and C. S. Tannenbaum. 1989. IFN-γ and
IFN-β independently stimulate the expression of lipopolysaccharide-inducible
genes in murine peritoneal macrophages. *J. Immunol. 142:2325.*

31. Tannenbaum, C. S., T. J. Koerner, M. M. Jansen, and T. A. Hamilton. 1988.
Characterization of lipopolysaccharide-induced macrophage gene expression.
J. Immunol. 140:3640.

32. Alexander, J. P., S. Kudoh, K. A. Melsop, T. A. Hamilton, M. G. Edinger,
R. R. Tubbs, D. Sica, L. Tauson, E. Klein, R. M. Bukowski, and J. H. Finke.
1993. T cells infiltrating renal cell carcinoma display a poor proliferative re-
sponse even though they can produce IL-2 and express IL-2 receptors. *Cancer
Res. 53:1380.*

33. Taub, D. D., A. R. Lloyd, K. Conlon, J. M. Wang, J. R. Ortaldo, A. Harada,
K. Matsushima, D. J. Kelvin, and J. J. Oppenheim. 1993. Recombinant human in-
terferon-inducible protein 10 is a chemoattractant for human monocytes and T lym-
phocytes and promotes T cell adhesion to endothelial cells. *J. Exp. Med. 177:1809.*

34. Podack, E. R., H. Hengartner, and M. G. Lichtenheld. 1991. A central role of
perforin in cytolysis? *Annu. Rev. Immunol. 9:129.*

35. Cesano, A., S. Visonneau, S. C. Clark, and D. Santoli. 1993. Cellular and mo-
lecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.
J. Immunol. 151:2943.

36. Salcedo, T. W., L. Azzoni, S. F. Wolf, and B. Perusia. 1993. Modulation of
perforin and granzyme messenger RNA expression in human natural killer cells.
J. Immunol. 151:2511.

37. Lowin, B., F. Beermann, A. Schmidt, and J. Tschopp. 1994. A null mutation in
the perforin gene impairs cytolytic T-lymphocyte and natural killer cell mediated
cytotoxicity. *Proc. Natl. Acad. Sci. USA 91:11571.*

38. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari,
H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human interferon inducible
protein IP-10 is a potent inhibitor of angiogenesis in vivo. *J. Exp. Med. 182:155.*

39. Luster, A. D., S. M. Greenberg, and P. Leder. 1995. The IP-10 chemokine binds
to a specific cell surface heparan sulfate site shared with platelet factor 4 and
inhibits endothelial cell proliferation. *J. Exp. Med. 182:219.*

40. Farber, J. M. 1997. Mig and IP-10: CXC chemokines that target lymphocytes.
J. Leukocyte Biol. 61:246.

41. Strieter, R. M., P. J. Polverini, S. L. Kunkel, D. A. Arenberg, M. D. Burdick,
J. Kasper, J. Dzuiba, J. Van Damme, A. Walz, and D. Marriott. 1995. The func-
tional role of the ELR motif in CXC chemokine-mediated angiogenesis. *J. Biol.
Chem. 270:27348.*

42. Voest, E. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and
J. Folkman. 1995. Inhibition of angiogenesis in vivo by IL-12. *J. Natl. Cancer
Inst. 87:581.*

43. Sgadari, C., A. L. Angiolillo, and G. Tosato. 1996. Inhibition of angiogenesis by
interleukin-12 is mediated by the interferon-inducible protein 10. *Blood 87:3877.*

44. Ozmen, L., M. Pericin, J. Hakimi, R. A. Chizzonite, M. Wysocka, G. Trinchieri,
M. Gately, and G. Garotta. 1994. Interleukin 12, interferon-γ, and tumor necrosis
factor α are the key cytokines of the generalized Shwartzman reaction. *J. Exp.
Med. 180:907.*

45. Orange, J. S., T. P. Salazar-Mather, S. M. Opal, R. L. Spencer, A. H. Miller,
B. S. McEwen, and C. A. Biron. 1995. Mechanism of interleukin 12-mediated
toxicities during experimental viral infections: role of tumor necrosis factor and
glucocorticoids. *J. Exp. Med. 181:901.*

46. Hendrzak, J. A., and M. J. Brunda. 1995. Interleukin-12: biologic activity, ther-
apeutic utility, and role in disease. *Lab. Invest. 72:619.*

47. Luster, A. D., and P. Leder. 1993. IP-10, A C-X-C-chemokine, elicits a potent
thymus-dependent antitumor response in vivo. *J. Exp. Med. 178:1057.*

48. Strieter, R. M., P. J. Polverini, D. A. Arenberg, A. Walz, G. Opdenakker,
J. Van Damme, and S. L. Kunkel. 1995. Role of C-X-C chemokines as regulators
of angiogenesis in lung cancer. *J. Leukocyte Biol. 57:752.*

49. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, S. B. Morris, M. D. Burdick,
M. C. Glass, D. T. Taub, M. D. Iannettoni, T. I. Whyte, and R. M. Strieter. 1996.
Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits
human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous me-
tastases. *J. Exp. Med. 184:981.*

50. Sgadari, C., A. Angiolillo, B. W. Cherney, S. E. Pike, J. M. Farber,
L. G. Koniaris, P. Vanguri, P. R. Burd, N. Sheik, G. Gupta, J. Teruya-Feldstein,
and G. Tosato. 1996. Interferon inducible protein 10 identified as a mediator of
tumor necrosis in vivo. *Proc. Natl. Acad. Sci. USA 93:13791.*

51. Sgadari, C., J. M. Farber, A. L. Angiolillo, F. Liao, J. Teruya-Feldstein,
P. R. Burd, L. Yao, G. Gupta, C. Kanegane, and G. Tosato. 1997. Mig, the monokine
induced by interferon-γ, promotes tumor necrosis in vivo. *Blood 89:2635.*

52. Huang, S., R. K. Singh, K. Xie, M. Gutman, K. K. Berry, C. D. Bucana,
I. J. Fidler, and M. Bar-Eli. 1994. Expression of the *JE/MCP-1* gene suppresses
metastatic potential in murine colon carcinoma cells. *Cancer Immunol. Immu-
nother. 39:231.*

53. Huang, S., K. Xie, R. K. Singh, M. Gutman, and M. Bar-Eli. 1995. Suppression
of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic
fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. *J. Interferon
Cytokine Res. 15:655.*

54. Manome, Y., P. Y. Wen, A. Hershowitz, T. Tanaka, B. J. Rollins, D. W. Kufe,
and H. A. Fine. 1995. Monocyte chemoattractant protein-1 (MCP-1) gene trans-
duction: an effective tumor vaccine strategy for non-intracranial tumors. *Cancer
Immunol. Immunother. 41:227.*

55. Rothenberg, M. E., A. D. Luster, and P. Leder. 1995. Murine eotaxin: an eosin-
ophil chemoattractant inducible in endothelial cells and in interleukin 4-induced
tumor suppression. *Proc. Natl. Acad. Sci. USA 92:8960.*

56. Laning, J., H. Kawasaki, E. Tanaka, Y. Luo, and M. Dorf. 1994. Inhibition of in
vivo tumor growth by the β chemokine TCA3. *J. Immunol. 153:4625.*

57. Rollins, B., and M. E. Sunday. 1991. Suppression of tumor formation in vivo by
expression of the JE gene in malignant cells. *Mol. Cell. Biol. 11:3125.*

58. Mule, J. J., M. Custer, B. Averbook, J. C. Yang, J. S. Weber, D. V. Goeddel,
S. A. Rosenberg, and T. J. Schall. 1996. RANTES secretion by gene modified
tumor cells results in loss of tumorigenicity in vivo: role of immune cell sub-
populations. *Hum. Gene Ther. 7:1545.*

59. Dilloo, D., K. Bacon, W. Holden, W. Zhong, W. Burdach, A. Zlotnik, and
M. Brenner. 1996. Combined chemokine and cytokine gene transfer enhances
anti-tumor immunity. *Nat. Med. 2:1090.*